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PURPOSE. Retinal melatonin synthesis occurs in the photorecep-
tor layer in a circadian manner, controlling several physiologic
rhythmic phenomena, besides being the most powerful natural
free radical scavenger. The purpose of the present work was to
evaluate the diurnal profile of retinal melatonin content and
the regulation of its synthesis in the retina of streptozotocin-
induced diabetic rats.
METHODS. Diabetes was induced in male Wistar rats (12
hour–12 hour light/dark cycle) with streptozotocin. Control,
diabetic, and insulin-treated diabetic animals were killed every
3 hours throughout the light–dark cycle. Retinal melatonin
content was measured by high-performance liquid chromatog-
raphy, arylalkylamine N-acetyltransferase (AANAT) activity was
analyzed by radiometric assay, Bmal1 gene expression was
determined by qPCR, and cyclic adenosine monophosphate
(cAMP) content was assessed by ELISA.
RESULTS. Control animals showed a clear retinal melatonin and
AANAT activity daily rhythm, with high levels in the dark.
Diabetic rats had both parameters reduced, and the impair-
ment was prevented by immediate insulin treatment. In addi-
tion, the Bmal1 expression profile was lost in the diabetic
group, and the retinal cAMP level was reduced 6 hours after
lights on and 3 hours after lights off.
CONCLUSIONS. The present work shows a melatonin synthesis
reduction in diabetic rats retinas associated with a reduction in
AANAT activity that was prevented by insulin treatment. The
Bmal1-flattened gene expression and the cAMP reduction
seem to be responsible for the AANAT activity decrease in
diabetic animals. The melatonin synthesis reduction observed
in the pineal gland of diabetic rats is also observed in a local
melatonin tissue synthesizer, the retina. (Invest Ophthalmol
Vis Sci. 2011;52:7416–7422) DOI:10.1167/iovs.10-6756
Melatonin (N-acetyl-5-methoxytryptamine), synthesizedmainly by the pineal gland, is also produced in the retina
of several vertebrate species. Retinal melatonin synthesis oc-
curs in a subpopulation of photoreceptors1 and, as observed in
the pineal gland, shows a clear daily variation with low levels
during the light period and high levels at night.2 Results of
previous studies have demonstrated that melatonin synthesis
pathway enzymes are under circadian control, at either tran-
scriptional or posttranscriptional levels in several species.3–7
ArylalKylamine N-acetyltransferase (AANAT) is the main reg-
ulatory enzyme in melatonin synthesis and both its mRNA level
and activity show a marked circadian variation in rat retina.5,8,9
The AANAT regulation is under the light–dark cycle and circa-
dian control. During the dark, increased intracellular cyclic
adenosine monophosphate (cAMP) stimulates Aanat gene ex-
pression through protein kinase A (PKA) activation and cAMP
response element-binding (CREB) phosphorylation and its in-
teraction with cAMP response element (CRE) in the Aanat
promoter.10 Besides that, increased cAMP and PKA activity
phosphorylate AANAT and promote its binding to 14-3-3 pro-
tein, possibly protecting it from proteolysis.11 The clock mech-
anism controls the rhythmic expression of AanatmRNA by the
interaction of the BMAL1:CLOCK complex with the E-box
present in the Aanat promoter.12 The circadian clock also
works as a gate, regulating rhythmic adenylyl cyclase (AC1)
mRNA expression and controlling the period during the day
when cAMP levels are maximally stimulated. In this way, mel-
atonin synthesis is exclusively gated to the night, by increased
Ca2 influx and stimulation of cAMP synthesis late in the day
and at night, when AC1 protein expression is high, but not
during the early morning.8
Several retinal physiologic phenomena were described as
rhythmic, including rod disc shedding,13 visual sensitivity,14
melatonin release in vivo2 and in vitro,1 dopamine synthesis,15
electroretinogram b-wave amplitude,16 extracellular pH,17 and
intraocular pressure.18 In addition, most retinal rhythms are
partially modulated by rhythmic melatonin and dopamine re-
lease.19–22
Melatonin is one of the most powerful natural free radical
scavengers,23 preventing oxidative damage to macromole-
cules, including lipids, proteins, and nucleic acids.24,25 Gu¨l et
al.26 have shown that melatonin reduces corneal injury in a
streptozotocin (STZ)-induced diabetic rat model. In an induced
ischemia model, melatonin blocks apoptosis in cultured human
retinal pigment epithelium (RPE) cells.27 In addition to the
potent antioxidant property of melatonin by itself, some of its
metabolites are themselves direct free radical scavengers,28,29
increasing melatonin’s antioxidant capacity. Besides that, mel-
atonin stimulates several antioxidant enzymes, including super-
oxide dismutase and glutathione peroxidase.25,30
In diabetes mellitus, the hyperglycemia increases the
enzymatic conversion of glucose to polyalcohol sorbitol,
with concomitant nicotinamide adenine dinucleotide phos-
phate (NADPH) and glutathione decrease,26 enhancing the
oxidative stress that may be involved in the development of
diabetic retinopathy.31
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Considering the essential function of melatonin on retinal
physiology and the functional interrelationship between insu-
lin and melatonin,32–35 we investigated the diurnal profile of
retinal melatonin content and AANAT activity in the retina of
STZ-induced diabetic rats.
To the best of our knowledge, this is the first evidence of
decreased melatonin production in retinas of STZ-induced di-
abetic rats.
MATERIALS AND METHODS
Animals
Male Wistar rats weighing 240 to 280 g were obtained from the
Institute of Biomedical Sciences, University of Sa˜o Paulo, Sa˜o Paulo,
Brazil. The animals were kept under a 12-hour:12-hour light–dark cycle
(lights on at 6 AM; Zeitgeber Time [ZT]0), in a temperature-controlled
room (21  2°C), with food and water ad libitum. Ethics approval was
granted for this study by the Committee of Ethics in Animal Experi-
mentation of the Institute of Biomedical Sciences, University of Sa˜o
Paulo, and it is in compliance with the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research.
Experimental Design and STZ-Induced Diabetes
Animals were divided into three groups: control, untreated diabetic,
and insulin (INS)-treated diabetic group. Diabetes was induced by a
single intraperitoneal injection of STZ (60 mg/kg body weight; Sigma-
Aldrich, St. Louis, MO) freshly diluted in citrate buffer (10 mM, Na
citrate; pH 4.5). Nondiabetic control rats were injected with citrate
buffer in the same volume. All the injections were performed during
the daytime. Body weight and glycemia were measured before and
after the STZ intraperitoneal injection. Tail blood was collected for
glucose determination using a glucometer (Optium Xceed; Medisense,
Abingdon, UK) after 24 hours of induction. Animals with glycemia
200 mg/dL were considered diabetic and included in the experimen-
tal group. INS-treated diabetic animals received 2 U subcutaneous
long-action insulin (Glargina/Lantus; Sanofi-Aventis, Paris, France) in
the beginning of the day and 2 U regular insulin (Humulin R; Eli Lilly,
Paris, France) plus 2 U long-acting insulin (Glargina/Lantus; Sanofi-
Aventis) in the beginning of the night. The treatment started 1 day after
diabetes induction, and the protocol was modified from Freitas et al.36
The STZ-induced diabetic condition was well established in our
rats, as can be evaluated by the high blood glucose concentrations
observed in the induced animals. No significant difference was found
between the INS-treated and control groups, showing that the insulin
treatment was capable of restoring the blood glucose concentration to
control levels (STZ-induced diabetic 361.7  76.78 mg/dL, n  49;
control 95.81  14.39 mg/dL, n  27; and INS-treated 130.1  78.74,
n  20; one-way ANOVA, P  0.0001, STZ-induced diabetic versus
control and INS-treated).
The effects of diabetes on retinal melatonin synthesis were evalu-
ated 3 days after STZ or citrate buffer injection. Independent groups of
control, STZ-induced diabetic and INS-treated diabetic animals were
killed every 3 hours throughout the 24-hour light–dark cycle.
Pinealectomy
To verify whether circulating melatonin levels influence the amount of
retinal melatonin we performed a pinealectomy (PINX), as previously
described.37 Control and PINX animals were killed during the dark
period at ZT12, -15, -18, -21, and -24, at 30 days after surgery.
Melatonin Levels Measurement
Retinal melatonin levels were measured by high-performance liquid
chromatography (HPLC) with electrochemical detection (Empower
software; Waters, Milford, MA).38 Melatonin was separated on a C18
column (5 m, 150 3.9 mm; Resolve; Waters). The chromatographic
system was isocratically operated with the following mobile phase: 0.1
M sodium acetate, 0.1 M citric acid, 0.15 mM ethylene diamine triacetic
acid (EDTA), and 35% methanol (pH 3.7), at a flow rate of 1 mL/min.
The electrochemical detector potential was adjusted to 900 mV. The
elution time for melatonin was approximately 6 minutes. Each retina
was sonicated (Microson XL 2005; Heat System, Inc., Farmingdale, NY)
in a solution of 0.1 M perchloric acid (120 L), containing 0.02% EDTA
and 0.02% sodium bisulfate. After centrifugation (2 minutes, 13,000g,
Eppendorf 5415C Centrifuge; Brinkman Instruments Inc., Westbury,
NY), 40 L of the supernatant was injected into the chromatographic
system (model 7125 Injector, 20-L loop; Rheodyne Inc., San Fran-
cisco, CA).
AANAT Activity Determination
AANAT activity was measured by a radiometric assay.39,40 Briefly, 100
L of 0.1 M sodium phosphate buffer (pH 6.8), containing 40 mM
tryptamine and [3H]-acetyl coenzyme A (2 mM; final specific activity
4 mCi/ mmol; Sigma-Aldrich), was added to a microcentrifuge tube
containing one retina kept at 4°C. The retinas were sonicated and then
incubated at 37°C for 20 minutes. The reaction product N- 3[H]-
acetyltriptamine was extracted with chloroform (1 mL). Samples of
500 L were evaporated until dry in a scintillation vial, and radioac-
tivity was determined (Tri-Carb 2100 Packard  counter; GMI Inc.,
Ramsey, MN).
Cell Viability and DNA Fragmentation
Retinas obtained from nondiabetic and diabetic rats killed by decapi-
tation were dissected, transferred to a phosphate buffer solution, and
incubated for 20 minutes at 37°C with 0.25% trypsin-EDTA (Invitrogen-
Gibco, Grand Island, NY). Enzymatic digestion was stopped by the
addition of Dulbecco’s modified Eagle’s medium (DMEM; Cultilab,
Campinas, SP, Brazil) containing 10 IU/mL penicillin, 10 g/mL strep-
tomycin, 10% fetal bovine serum, 2 mM glutamine, and 25 mM glucose.
Tissue was mechanically dissociated with a micropipette, and cells
were evaluated as describe below.
TABLE 1. Primer Sequences for Rat Bmal1, Actb, Rp137 and Actg1, Real-Time Quantitative
RT-PCR Assays
Target and Reference Genes RefSeq Sequence
Bmal 1 (Arntl) NM_024362.2 5-CCGATGACGAACTGAAACACC-3
5-TCTTCCCTCGGTCACATCCT-3
Actb NM_031144 5-CTAGGAGCCAGGGCAGTAATCT-3
5-AAGACCTCTATGCCAACACAGTG-3
Rpl37a NM_001108801 5-CGCTAAGTACACTTGCTCCTTCTG-3
5-GCCACTGTTTTCATGCAGGAAC-3
Actg1 NM_001127449 5-TACCCTATTGAGCACGGCAT-3
5-CGCAGCTCGTTGTAGAAGGT-3
RefSeq is provided by the National Center for Biotechnology Information, Bethesda, MD
(www.ncbi.nlm.nih.gov/locuslink/refseq/).
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Rat retina cells were washed and suspended in phosphate-buffered
saline (PBS). Afterward, 50 L of propidium iodide solution (50 mg/mL
in PBS) was added, and the cells were analyzed with flow cytometry
(FACSCalibur; BD Biosciences, San Jose, CA). Fluorescence was mea-
sured using the FL2 channel (orange-red fluorescence; 585/42 nm).
Ten thousand events were analyzed per experiment. Cells with pro-
pidium iodide fluorescence were then evaluated (Cell Quest software;
BD Biosciences). DNA fragmentation was calculated after DNA staining
with propidium iodide according to a method previously described.41
The pellet was gently resuspended in 300 L hypotonic solution
containing 50 mg/mL propidium iodide, 0.1% sodium citrate, and 0.1%
Triton X-100. The cells were then incubated for 1 hour at room
temperature. Fluorescence was measured and analyzed as described
above.
cAMP Immunoassay
Retinas were homogenized in 0.1 M HCl using a homogenizer
(Polytron; VWR International, Lutterworth, UK). After 5 minutes of
centrifugation, the supernatants were collected and assayed directly
according to the kit protocol (BioVision Research Products, Moun-
tain View, CA).
Real-Time Quantitative PCR
Retinal total RNA was isolated using a guanidine isothiocyanate–based
reagent (Trizol; Invitrogen Corp., Carlsbad, CA), according to the
manufacturer’s specifications. Total RNA was eluted in RNase-free
water, treated with DNase genomic DNA remover (Turbo DNA-free;
Ambion, Austin, TX) according to the manufacturer’s specifications.
Reverse transcriptase (200 U Superscript III; Invitrogen Corp.), DTT
(10 nM), dNTP (10 mM each), RNase inhibitor (40 U), and random
primers (150 ng) were used to reverse transcribe 1 g of total RNA in
a final reaction volume of 20 L. qRT-PCR was performed (7500
Real-Time PCR System; Applied Biosystems, Inc. [ABI], Foster City, CA)
with 25-L reactions containing 2 L of cDNA (10 ng/L), SYBR green
(Power SYBR Green; ABI), and 400 nM specific intron-spanning prim-
ers (Table 1). The cycling parameters included an initial denaturation
step at 95°C for 10 minutes, followed by 40 cycles of 95°C for 15
seconds and annealing and extension at 60°C for 1 minute. Melting
curve analyses (Tm) and ethidium bromide (EtBr)-agarose gel (2.2%
wt/vol) electrophoresis of the amplified products were performed for
product specificity assessment. A set of 10-fold serial dilutions of each
internal standard (101–107 copies/2 L) was used to generate a stan-
dard curve, and all qRT-PCR assays were linear within this concentra-
tion range with correlation coefficients (r2  0.999). Transcript num-
bers were determined by the system software (model 7500, ver. 2.0.3;
ABI) and normalized using the geometric mean calculated from the
reference genes Actb, Rpl37a, and Actg1, which were indicated as the
most suitable ones by the software GeNorm.42
Statistics
All the results were plotted as the mean  SEM. One-way ANOVA was
used to evaluate the influence of the variable “time of day” on each
temporal series, two-way ANOVA with Bonferroni’s posttest was used
to compare groups regarding the factors time of day, treatment (con-
trol, diabetic, and INS-treated), and the interaction between them.
Student’s t-test was used when appropriate (all statistical tests and
graphics: Prism, ver. 5.01 for Windows; GraphPad Software, San Diego,
CA). Results are representative of at least two independent experimen-
tal blocks.
RESULTS
Cell Viability and DNA Fragmentation
The flow cytometer results showed that 3 days of STZ-induced
diabetes did not cause retinal cell necrosis (viability test) or
retinal cell apoptosis (DNA fragmentation test) when com-
pared to control group values (Fig. 1).
Daily Retinal Melatonin Profile after 3 Days of
STZ-Induced Diabetes
As expected, retinas of the control animals showed a clear daily
rhythm of melatonin synthesis, with high levels during the
night and low levels during the day (Fig. 2). In the retinas of the
diabetic rats, a nearly 40% reduced melatonin synthesis at ZT18
(P  0.01) and ZT21 (P  0.05) was observed compared with
that of the control (Fig. 2). On the other hand, insulin treat-
ment prevented melatonin reduction, since no statistical sig-
nificance was found between the control and INS-treated dia-
betic animals after 3 days of treatment (Fig. 2).
Retinal Melatonin from PINX and Intact Animals
As can be observed in Figure 3, there was no difference in the
retinal melatonin content of the PINX and intact animals. This
finding leads us to conclude that pineal melatonin does not
influence the amount of retinal melatonin in rats.
Daily AANAT Activity Profile after 3 Days of
STZ-Induced Diabetes
In an attempt to investigate why retinal melatonin is re-
duced in diabetic rats, we analyzed the daily AANAT activity
profile. The AANAT activity of the control group presented
FIGURE 1. Cell viability (A) and
DNA fragmentation (B) after 3 days
of STZ-induced diabetes; n  10 con-
trol and n  6 diabetic animals, plot-
ted as the mean  SEM.
FIGURE 2. Daily retinal melatonin profile. Retinas were collected ev-
ery 3 hours throughout the light–dark cycle after 3 days of STZ-
induced diabetes; n  12 control, n  12 diabetic, and n  3
INS-treated diabetic retinas per time point. Two-way ANOVA with
Bonferroni’s multiple-comparison posttest: P  0.05 for the treatment
factor, P  0.0001 for the ZT factor, and P  0.005 for the interaction.
**P  0.01 *P  0.05 vs. diabetic; plotted as the mean  SEM.
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higher values in the dark period at ZT15 (P  0.01) and
lower levels in the light period at ZT6 (P  0.01) in com-
parison to that in the diabetic group (Fig. 4). On the other
hand, the retinal AANAT activity daily fluctuation that was
abolished in rats with STZ-induced diabetes was completely
restored in the INS-treated group.
Daily Retinal Bmal1 mRNA and cAMP Content
after 3 Days of STZ-Induced Diabetes
Bmal1 gene expression and cAMP content analysis were per-
formed to elucidate the AANAT activity reduction observed in
the diabetic group (Fig. 5).
Our data show Bmal1 that gene expression was high in the
middle of the day (ZT6) and at ZT12, -15, and -18 in the control
group. In the diabetic group, this pattern of expression van-
ished completely (Fig. 5A). The retinal cAMP level was signif-
icantly reduced at ZT6 (P  0.001) and at ZT15 (P  0.001) in
the diabetic group, in comparison with that in the control
group (Fig. 5B).
Retinal Melatonin and AANAT Activity at ZT18
after 15 Days of STZ-Induced Diabetes
To verify whether the reduction of retinal melatonin content
and AANAT activity persists, we analyzed both parameters at
ZT18 after 15 days of STZ-induced diabetes (Fig. 6). We
observed a 75% reduction in the retinal melatonin content
and a decrease in AANAT activity in the diabetic animals
compared with that in the control animals after 15 days of
induction.
DISCUSSION AND CONCLUSIONS
Several studies have shown the protective properties of mela-
tonin in retinas of STZ-induced diabetic rats.24,26,43 Our work
is the first to show the effects of STZ-induced diabetes on
retinal melatonin synthesis.
In the present work, the STZ-induced diabetic condition
was established in our rats and verified by high blood glucose
concentrations and hypoinsulinemia (data not shown). The
insulin treatment was capable of restoring the blood glucose
concentration to control levels.
Initially, the cellular viability and DNA fragmentation of
retinas from control and diabetic rats did not show any
significant statistical difference, validating the study of reti-
nal melatonin synthesis in the STZ-induced diabetes model.
Park et al.44 showed, in an STZ-induced diabetes model,
degenerative changes from 1 week onward in postsynaptic
processes of horizontal cells in the deep invaginations of the
photoreceptor cell layer, where melatonin synthesis takes
place. The same group reported photoreceptor cell apopto-
sis after 4 weeks of disease. Based on these studies, it is
unlikely that a level of retinopathy is established after 3 days
of diabetes that could affect the results that we obtained.
However, we have to consider that flow cytometry does not
specifically evaluate the photoreceptors, which are the mel-
atonin-synthesizing cells.
The circadian profile of retinal melatonin content observed
in the control group corroborates that found by Tosini and
Menaker.1 On the other hand, we showed a 40% reduction on
the nocturnal retinal melatonin content in the STZ-induced
diabetic group in comparison to the control. Moreover, the
reduction in the retinal AANAT activity corresponded to the
reduced melatonin synthesis. In addition, when the animals
had their diabetes treated by the administration of insulin, we
found a complete reestablishment of both the melatonin syn-
thesis profile and AANAT activity. Furthermore, we demon-
strated a reduction in melatonin synthesis and AANAT activity
15 days after STZ induction.
There is no information in the literature about retinal mel-
atonin synthesis in diabetic rats; the available data concern
pineal melatonin synthesis in different diabetes models. In
accordance with our results in the retina, some reports de-
scribed a significant reduction of pineal melatonin synthesis in
diabetic rats induced by alloxan or STZ (Amaral FG, personal
communication, 2010)45,46 as well as in hamsters.47,48 De-
creased plasma melatonin levels were found in type 1 diabetic
patients,49,50 in type 2 diabetic patients, and in type 2 diabetic
rats.51
In an attempt to elucidate whether the reduced plasma
melatonin content observed in diabetic rats would explain
the reduced levels of retinal melatonin in our diabetic ani-
mals, we analyzed the retinal melatonin content in pinealec-
tomized rats and compared it with that in control animals.
No difference was found between the groups, so it is pos-
sible to conclude that the melatonin measured in the retina
is exclusively of retinal origin. In this regard, the melatonin
reduction found in the diabetic group retinas is most prob-
ably due to the impaired intrinsic mechanism of melatonin
synthesis in the retina that led us to proceed with the
analysis of retinal AANAT activity.
Considering the AANAT activity profile in the retinas, our
results are in agreement with those of Niki et al.,9 who dem-
onstrated the circadian pattern of this enzyme activity. STZ-
induced diabetic rats showed a loss of AANAT activity rhyth-
micity, which was partially restored in INS-treated animals.
Although insulin treatment did not totally recover the control
AANAT activity pattern, the melatonin content results show
that insulin reposition was able to recover not only the retinal
melatonin level, but also the rhythmic pattern that is observed
FIGURE 4. Daily retinal AANAT activity profile. Retinas were collected
every 3 hours throughout the light–dark cycle after 3 days of STZ-
induced diabetes: n  12 control, n  12 diabetic, and n  3
INS-treated diabetic rat retinas per time point. Two-way ANOVA with
Bonferroni’s multiple-comparison posttest: P  0.4360 for the treat-
ment factor, P  0.0001 for the ZT factor, and P  0.0001 for the
interaction. ***P  0.001 vs. control, **P  0.01 vs. diabetic, *P  0.05
vs. control and diabetic, plotted as the mean  SEM.
FIGURE 3. Retinal melatonin from PINX and intact control animals;
n  16 plotted as the mean  SEM.
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in control rats. Thus, the AANAT activity peak found at ZT15
supports the melatonin synthesis peaks observed at ZT18 and
-21 in INS-treated animals. Reinforcing our data, Lynch et al.52
showed that insulin was able to increase pineal AANAT activity
and consequently plasma levels of melatonin. The same was
observed by Peschke et al.51 in Goto Kakizaki rats with spon-
taneous diabetes. Moreover, Garcia et al.34 and Peliciari-Garcia
et al.35 demonstrated, in vitro, that insulin is able to potentiate
the norepinephrine-induced melatonin synthesis in the rat pi-
neal gland via phosphatidylinositol-3 kinase (PI3K) signaling
and AANAT activity.
It is known that the BMAL1:CLOCK complex is involved
in AC1 and Aanat gene expression regulation and the cAMP
signaling pathway is crucial for AANAT stability. Our data
show high Bmal1 gene expression in the middle of the day
(ZT6) and at ZT12, -15, and -18 in the control group. This
multipeaked control profile is probably due to the measure-
ment of Bmal1 mRNA levels in the whole retina, not just in
the melatonin-synthesizing cells. The retina is a multilayered
tissue that contains different cell types, and Bmal1 expres-
sion has been detected in the photoreceptors, the inner
nuclear layer, and the ganglion cell layer.53
In the diabetic retinas, the variation in the daily expres-
sion of Bmal1 was lost in comparison with that in the
control retinas, leading us to suppose that this flattened
Bmal1 expression could impair the AC1 levels, resulting in
the observed decrease in cAMP level and consequent
AANAT activity reduction at ZT15. Moreover, Aanat gene
expression may also be affected by the flattened Bmal1
expression contributing to the arrhythmic AANAT activity
and reduction observed (Fig. 7).
Recent data from the literature suggest that both Clock
and Bmal1 participate in the regulation of energy metabo-
lism.54 Young et al.55 showed that STZ-induced diabetes is
associated with alterations in the circadian clock of the rat
heart. Further experiments are under way to evaluate cAMP
decline and how the retinal circadian clock is affected by
diabetes.
There are no data in the literature that show the effects of
diabetes on the retinal melatonin synthesis pathway. On the
other hand, it has been reported that retinal insulin signaling is
in a constitutively higher steady state and that the basal phos-
phorylation and activity of the insulin receptor and serine/
threonine protein kinase (Akt) maintain a tonic cell-survival
signal in the metabolically active retina.56 Diabetes induced by
STZ treatment gives rise to late neural cell death in the retina,
but it is has not been established yet whether this effect is
directly related to reduced circulating insulin, or the reduction
of insulin increases apoptosis by an indirect mechanism such
as hyperglycemia.57 Considering our results, we do not know
whether there is a direct action of insulin in the retinal mela-
tonin synthesis pathway, or the effect is caused by hypergly-
cemia, or both factors contribute. Insulin treatment prevented
a reduction in melatonin synthesis, but it also controlled the
hyperglycemia.
Although additional studies are necessary to clarify the
mechanisms underlying the decreased insulin and consequent
hyperglycemia involvement in the retinal melatonin synthesis
impairment, it is important to note that the melatonin synthesis
reduction already reported in the pineal gland of STZ-induced
diabetic rats is also observed in a local melatonin tissue syn-
thesizer, the retina.
In this way, in the presence of diabetes, the reduction of
local melatonin synthesis, a powerful natural antioxidant,
may contribute, in addition to the well-known impairment
FIGURE 5. Daily retinal Bmal1 gene expression (A) and cAMP amount profile (B). Retinas were
collected every 3 hours throughout the light–dark cycle after 3 days of STZ-induced diabetes: n  3
control and n  3 diabetic rat retinas per time point. Two-way ANOVA followed by Bonferroni’s
multiple-comparison posttest: (A) P  0.0001 for the treatment factor, P  0.0001 for the ZT factor,
and P  0.0001 for the interaction. (B) P  0.0001 for the treatment factor, P  0.0001 for the ZT
factor and P  0.0005 for the interaction. **P  0.001, *** P  0.0001 vs. control, plotted as the
mean  SEM.
FIGURE 6. Retinal melatonin (A)
and AANAT activity (B) from control
and 15 days STZ-induced diabetic
rats. Retinas were collected at ZT18,
n  10. Two-tailed Student’s t-test,
***P  0.0001 vs. control, plotted as
the mean  SEM.
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in retinal antioxidant defense, to the development of dia-
betic retinopathy, a frequent complication of this disease.
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